Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck Cancer
Sponsor: Bristol-Myers Squibb
This PHASE2 trial investigates Head and Neck Squamous Cell Carcinoma (HNSCC) and is currently actively recruiting participants. Bristol-Myers Squibb leads this study, which shows 19 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
19 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 14 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2023 [monthly]
Recruiting PHASE2
-
Nov 2021 — May 2022 [monthly]
Recruiting PHASE2
-
May 2021 — Nov 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE2
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Dan Zandberg
For direct contact, visit the study record on ClinicalTrials.gov .